Paneth cell

EQS-News: Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

Retrieved on: 
Saturday, May 6, 2023
Molecule, Paneth cell, Gastrointestinal disease, Histology, Diarrhea, Gastrointestinal tract, Epithelium, Biotechnology, Clinical trial, Irritable bowel syndrome, Biomarker, Ulcerative colitis, DDW, Regeneration, Enterocyte, Patient, Action, Poster, B cell, Coeliac disease, DSS, Vaccine, Pharmaceutical industry, Paneth, Short course immune induction therapy, SIRT6

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

Key Points: 
  • Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
    The issuer is solely responsible for the content of this announcement.
  • The presentation will be held as a virtual e-poster at Digestive Disease Week (DDW) 2023, currently underway through Tuesday, May 9, 2023, both virtually and in-person, in Chicago, IL.
  • In both animal and early clinical studies, IMU-856 has been shown to restore and renew the intestinal lining.
  • Immunic reported that IMU-856 treatment showed beneficial effects in four key dimensions of celiac disease pathophysiology: histology, disease symptoms, biomarkers and nutrient absorption.

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

Retrieved on: 
Saturday, May 6, 2023
Molecule, Paneth cell, Histology, Diarrhea, Gastrointestinal tract, Epithelium, Clinical trial, Irritable bowel syndrome, Biomarker, Ulcerative colitis, DDW, Crohn's disease, Regeneration, Enterocyte, Patient, Poster, B cell, Coeliac disease, Phenotype, DSS, Pharmaceutical industry, Vaccine, Paneth, Short course immune induction therapy, SIRT6

NEW YORK, May 6, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of clinical and preclinical data for IMU-856. Included in this presentation are new data on IMU-856's mode of action as a potent modulator of SIRT6 (Sirtuin 6), a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. The presentation will be held as a virtual e-poster at Digestive Disease Week (DDW) 2023, currently underway through Tuesday, May 9, 2023, both virtually and in-person, in Chicago, IL.

Key Points: 
  • The presentation will be held as a virtual e-poster at Digestive Disease Week (DDW) 2023, currently underway through Tuesday, May 9, 2023, both virtually and in-person, in Chicago, IL.
  • In both animal and early clinical studies, IMU-856 has been shown to restore and renew the intestinal lining.
  • Immunic reported that IMU-856 treatment showed beneficial effects in four key dimensions of celiac disease pathophysiology: histology, disease symptoms, biomarkers and nutrient absorption.
  • That said, we are preparing for a phase 2b clinical trial of IMU-856 in celiac disease patients, while also considering other indications."

VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease

Retrieved on: 
Wednesday, October 20, 2021
Short bowel syndrome, GI, IND, Acquisition, Liver, Paneth cell, Metabolism, SBS, Form, Inborn errors of metabolism, COVID-19, Nutrient, Lists of diseases, Investigational New Drug, U.S. Securities and Exchange Commission, Patient, Phrase, Manufacturing execution system, Security (finance), Skin, Drug development, GVHD, Failure, Disease, Community of Metros, III, Interim, FDA, Nasdaq, Paneth, PS, GLOBE, Congenital disorders of amino acid metabolism, Survival, MMA, Graft-versus-host disease, Forward-looking statement, Compliance, University Medical Center Freiburg, Cancer, Food, HSCT, COA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Propionic acidemia, Mortality, Safety, Pharmaceutical industry

BASEL, Switzerland, Oct. 20, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to evaluate apraglutide, a next-generation, long-acting GLP-2 analog, in a Phase 2 clinical trial called STARGAZE (Study of Apraglutide in Graft-Versus-Host Disease), for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD).

Key Points: 
  • We have demonstrated promising preclinical results with apraglutide as a novel approach to treating acute graft-versus-host disease, showing a significant reduction in mortality after treatment with apraglutide in mouse models.
  • STARGAZE, a Phase 2, randomized, double-blind study, will assess the safety, tolerability, pharmacokinetic profile and efficacy of apraglutide in patients with steroid-refractory aGVHD.
  • Apraglutide is also being evaluated in steroid-refractory acute graft-versus-host disease (aGVHD) and has demonstrated improvements in survival in pre-clinical aGVHD models.
  • It is being developed for a range of rare gastrointestinal diseases where GLP-2 plays a central role in disease pathophysiology, including Acute Graft-Versus-Host Disease (aGVHD).